PL3727429T3 - Leczenie zaburzeń autonomicznych toksyną botulinową - Google Patents

Leczenie zaburzeń autonomicznych toksyną botulinową

Info

Publication number
PL3727429T3
PL3727429T3 PL18825698.6T PL18825698T PL3727429T3 PL 3727429 T3 PL3727429 T3 PL 3727429T3 PL 18825698 T PL18825698 T PL 18825698T PL 3727429 T3 PL3727429 T3 PL 3727429T3
Authority
PL
Poland
Prior art keywords
treatment
botulinum toxin
autonomic disorders
autonomic
disorders
Prior art date
Application number
PL18825698.6T
Other languages
English (en)
Inventor
Johannes Krupp
Jacquie MAIGNEL-LUDOL
Bernadette Pignol
Original Assignee
Ipsen Biopharm Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Limited filed Critical Ipsen Biopharm Limited
Publication of PL3727429T3 publication Critical patent/PL3727429T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18825698.6T 2017-12-20 2018-12-20 Leczenie zaburzeń autonomicznych toksyną botulinową PL3727429T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306840 2017-12-20
PCT/EP2018/086261 WO2019122166A1 (en) 2017-12-20 2018-12-20 Treatment of autonomic disorders with botulinum toxin

Publications (1)

Publication Number Publication Date
PL3727429T3 true PL3727429T3 (pl) 2025-08-25

Family

ID=61027399

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18825698.6T PL3727429T3 (pl) 2017-12-20 2018-12-20 Leczenie zaburzeń autonomicznych toksyną botulinową

Country Status (21)

Country Link
US (2) US20200377872A1 (pl)
EP (2) EP3727429B1 (pl)
JP (4) JP7162059B2 (pl)
KR (1) KR20200100625A (pl)
CN (1) CN111491659A (pl)
AR (1) AR113983A1 (pl)
AU (2) AU2018392818C1 (pl)
BR (1) BR112020005186A2 (pl)
CA (1) CA3083069A1 (pl)
DK (1) DK3727429T3 (pl)
EA (1) EA202091527A1 (pl)
ES (1) ES3036736T3 (pl)
FI (1) FI3727429T3 (pl)
HU (1) HUE071806T2 (pl)
MA (1) MA51279A (pl)
MX (1) MX2020006043A (pl)
PL (1) PL3727429T3 (pl)
PT (1) PT3727429T (pl)
SG (1) SG11202002876WA (pl)
TW (1) TWI810228B (pl)
WO (1) WO2019122166A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202001353D0 (en) * 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
TWI825396B (zh) * 2020-03-16 2023-12-11 英商艾普森生物製藥有限公司 肢體痙攣之治療
GB202206353D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
JP2025534349A (ja) * 2022-09-30 2025-10-15 イプセン バイオファーム リミテッド 膀胱痛症候群の治療

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ATE518882T1 (de) 2005-09-19 2011-08-15 Allergan Inc Mit clostridientoxin aktivierbare clostridientoxine
UA116985C2 (uk) 2012-05-30 2018-06-11 Президент Енд Феллоуз Оф Гарвард Колледж Рекомбінантний ботулінічний нейротоксин
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PT3274364T (pt) * 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201505306D0 (en) * 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
IL263058B2 (en) * 2016-06-08 2023-11-01 Childrens Medical Center Engineered botulinum neurotoxins
CN109106957A (zh) * 2018-11-08 2019-01-01 自贡德西玛医疗设备有限公司 一种旋转增效的高温消毒系统

Also Published As

Publication number Publication date
MA51279A (fr) 2021-03-31
AU2018392818A1 (en) 2020-03-19
FI3727429T3 (fi) 2025-07-04
JP2021504301A (ja) 2021-02-15
WO2019122166A1 (en) 2019-06-27
ES3036736T3 (en) 2025-09-23
BR112020005186A2 (pt) 2020-09-15
PT3727429T (pt) 2025-06-12
EP4591933A3 (en) 2025-10-22
EP3727429B1 (en) 2025-05-07
JP2022191409A (ja) 2022-12-27
JP7659676B2 (ja) 2025-04-09
TWI810228B (zh) 2023-08-01
JP7445725B2 (ja) 2024-03-07
JP2024059821A (ja) 2024-05-01
KR20200100625A (ko) 2020-08-26
US20250101397A1 (en) 2025-03-27
CN111491659A (zh) 2020-08-04
AU2025202320A1 (en) 2025-04-17
AU2018392818B2 (en) 2025-01-16
CA3083069A1 (en) 2019-06-27
HUE071806T2 (hu) 2025-09-28
JP2025098207A (ja) 2025-07-01
SG11202002876WA (en) 2020-07-29
JP7162059B2 (ja) 2022-10-27
TW202017590A (zh) 2020-05-16
US20200377872A1 (en) 2020-12-03
MX2020006043A (es) 2020-08-17
EA202091527A1 (ru) 2020-09-11
EP3727429A1 (en) 2020-10-28
DK3727429T3 (da) 2025-07-21
AR113983A1 (es) 2020-07-08
EP4591933A2 (en) 2025-07-30
AU2018392818C1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
IL271085A (en) Bacteria for the treatment of disorders
IL285151A (en) Methods of treating fgf21-associated disorders
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
IL290994A (en) Methods of diagnosing and treating conduct disorder
PL3265053T3 (pl) Sposoby leczenia skóry
IL263680A (en) Combination therapies
IL262852A (en) Treatment of complement-mediated disorders
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
HUE056287T2 (hu) Pancreatitis kezelése
IL304733A (en) Improved use of botulinum neurotoxin in the treatment of sialorrhea
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
LT3307267T (lt) Išsėtinės sklerozės gydymas
DK3408265T3 (da) Terapeutiske forbindelser
IL270900A (en) Treatment of cutaneous disorders
EP3597225A4 (en) TREATMENT PROCESS
IL254825A0 (en) Methods of treatment with taselisib
PL3727429T3 (pl) Leczenie zaburzeń autonomicznych toksyną botulinową
DK3302478T3 (da) Pac-1 kombinations behandling
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
IL263080B (en) Treatment of neurological disorders
PL3727423T3 (pl) Leczenie zaburzeń metabolicznych z użyciem wariantów fgf21
ITUA20161679A1 (it) Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
PL3131549T3 (pl) Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme